Abbott: Abbott Labs: Annual EPS in line with expectations

Abbott Laboratories reports fourth-quarter 2024 adjusted EPS in line with expectations at $1.34, bringing the year-to-date figure to $4.67, in line with its target range of three months ago ($4.64-4.70). The healthcare group reported revenues of $11 billion in the last quarter (+10.1% organic on an underlying basis), for a total of $42 billion for the year, up 9.6% on an adjusted basis (against a target range of 9.5-10%). For the year ahead, Abbott Labs expects adjusted EPS of $5.05 to $5.25, a non-GAAP operating margin of 23.5% to 24% (+150 basis points at the mid-point) and organic revenue growth of 7.5% to 8.5%. Copyright (c) 2025 CercleFinance.com. All rights reserved.